ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

Source: IMMUNO-ONCOLOGY NEWS, September 2019

Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest.

The trial is testing a combination of ONCOS-102 and the immune checkpoint inhibitor Keytruda (pembrolizumab) in advanced or surgery-ineligible melanoma patients whose tumor continued to progress despite treatment with an anti PD-1 antibody, such as Keytruda or Opdivo (nivolumab).

Early results showed that the combination reduced tumor size in three of the nine patients enrolled, including one patient whose disease completely disappeared.

Read the original full article